Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (NCT07223593)
A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Who can join: Review the eligibility criteria below.
Location: St. Vincent's Birmingham Hospital — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (159 Sites)
Showing the first 25 of 159 sites.
- St. Vincent's Birmingham Hospital — Birmingham, Alabama
- Mercy Gilbert Medical Center — Gilbert, Arizona
- Emvera Health at Peak Heart & Vascular Surprise — Surprise, Arizona
- Del Sol Research Management, LLC — Tucson, Arizona
- Angel City Research Inc. — Los Angeles, California
- Valley Clinical Trials, LLC dba Flourish Research — Northridge, California
- The Cardiovascular Center — Redding, California
- InvivoCure — Van Nuys, California
- Interventional Cardiology Medical Group — West Hills, California
- Rocky Mountain Regional VA Medical Center — Aurora, Colorado
- Lakeview Institute of Clinical Research — Leesburg, Florida
- Inpatient Research Clinic — Miami Lakes, Florida
- Floridian Clinical Research, LLC — Miami Lakes, Florida
- St Johns Center for Clinical Research — Saint Augustine, Florida
- ASHA Clinical Research - Munster, LLC — Hammond, Indiana
- Indiana University Health Methodist Hospital — Indianapolis, Indiana
- Cardiovascular Research of Northwest Indiana — Munster, Indiana
- Deaconess Clinic- Gateway — Newburgh, Indiana
- Flourish Research - Bowie — Bowie, Maryland
- Capitol Cardiology Associates - Lanham Office — Lanham, Maryland
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division — Troy, Michigan
- Capital Area Research, LLC — Camp Hill, Pennsylvania
- The Jackson Clinic — Jackson, Tennessee
- East Coast Institute for Research - Jefferson City — Jefferson City, Tennessee
- Biopharma Informatic, LLC — Houston, Texas
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Peripheral Arterial Disease
- SELUTION4SFA Trial — Little Rock, Arkansas
- SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs — New Haven, Connecticut
- A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND) — Birmingham, Alabama
- Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy — Indianapolis, Indiana
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease — Chicago, Illinois
- MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology — Omaha, Nebraska
Explore by condition: All Peripheral Arterial Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.